BPS Bioscience, Inc.

BPS Bioscience, Inc. ("BPS") announces a new, low-cost program to make recombinant immunotherapy cell lines available for short-term projects

BPS Bioscience, Inc. (“BPS”) announces the addition of a one-of-a-kind assay kit designed to screen for inhibitors of IL-17A interaction with IL-17RA.

Identify Histone Demethylase Inhibitors against the largest panel available with BPS Bioscience

Adding to an already extensive offering of Immunotherapy products, BPS Bioscience, Inc. (BPS) now provides over 15 exclusive biotin-labeled immunotherapy proteins

BPS Bioscience, Inc. (“BPS”) announces Ebola virus glycoproteins for drug discovery research use.

BPS Bioscience, Inc. (“BPS”) announces new kits for screening inhibitors of the histone demethylases FBXL10 & FBXL11 and the histone methyltransferase SETDB1. These unique kits join a large portfolio of kits and proteins for epigenetic research.

BPS Bioscience, Inc. (BPS) is now offering a KEAP1:Nrf2 Inhibitor Screening Assay Kit

BPS Bioscience, Inc. (BPS) is now offering its newest cell line: the Hippo Pathway TEAD Reporter – MCF7 Cell Line.

BPS Bioscience, Inc. (“BPS”) has developed several new assay kits (BTLA:HVEM, CD28:B7-1, and CTLA4:B7-1) and related proteins to advance immunotherapy research.

BPS Bioscience, Inc. introduces unique EZH2 mutants and 2 new assay kits for screening EZH2 inhibitors